SG11201703024VA - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonistsInfo
- Publication number
- SG11201703024VA SG11201703024VA SG11201703024VA SG11201703024VA SG11201703024VA SG 11201703024V A SG11201703024V A SG 11201703024VA SG 11201703024V A SG11201703024V A SG 11201703024VA SG 11201703024V A SG11201703024V A SG 11201703024VA SG 11201703024V A SG11201703024V A SG 11201703024VA
- Authority
- SG
- Singapore
- Prior art keywords
- glucocorticoid
- receptor antagonists
- liver disease
- fatty liver
- disease treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703024VA true SG11201703024VA (en) | 2017-05-30 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703024VA SG11201703024VA (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US10238659B2 (pt) |
| EP (2) | EP4353310A3 (pt) |
| JP (1) | JP6761410B2 (pt) |
| KR (1) | KR102435956B1 (pt) |
| CN (2) | CN107106562B (pt) |
| AU (1) | AU2015333645B2 (pt) |
| BR (1) | BR112017007860B1 (pt) |
| CA (1) | CA2964625C (pt) |
| DK (1) | DK3206692T3 (pt) |
| ES (1) | ES2978871T3 (pt) |
| FI (1) | FI3206692T3 (pt) |
| IL (1) | IL251729B (pt) |
| MX (1) | MX2017004943A (pt) |
| NZ (1) | NZ731060A (pt) |
| PH (1) | PH12017500710A1 (pt) |
| PL (1) | PL3206692T3 (pt) |
| PT (1) | PT3206692T (pt) |
| RU (1) | RU2718921C2 (pt) |
| SG (1) | SG11201703024VA (pt) |
| UA (1) | UA123537C2 (pt) |
| WO (1) | WO2016061195A1 (pt) |
| ZA (1) | ZA201702813B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964625C (en) | 2014-10-15 | 2023-03-07 | Corcept Therapeutics, Inc. | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| JP7196201B2 (ja) * | 2018-06-04 | 2022-12-26 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子 |
| CN115515569A (zh) * | 2020-05-06 | 2022-12-23 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂的制剂 |
| IL297839A (en) * | 2020-05-06 | 2023-01-01 | Corcept Therapeutics Inc | Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| IL303881A (en) * | 2020-12-21 | 2023-08-01 | Corcept Therapeutics Inc | METHOD FOR PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS |
| AU2022271209A1 (en) * | 2021-05-05 | 2023-11-09 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| EP1883624B1 (en) | 2005-05-18 | 2010-04-07 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| EP2923699B1 (en) | 2006-05-09 | 2018-06-20 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| MX2009011062A (es) | 2007-04-13 | 2009-10-29 | Schering Corp | Derivados de pirimidindiona y sus metodos de uso. |
| WO2009155481A1 (en) | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| EP2414356B1 (en) | 2009-04-03 | 2015-09-02 | F.Hoffmann-La Roche Ag | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
| EP2685827B1 (en) | 2011-03-18 | 2016-02-03 | Corcept Therapeutics, Inc. | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| CA2964625C (en) | 2014-10-15 | 2023-03-07 | Corcept Therapeutics, Inc. | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en active Application Filing
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active IP Right Grant
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-17 PH PH12017500710A patent/PH12017500710A1/en unknown
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US20230218621A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246304A1 (zh) | 包含抗cd73抗體和a2a受體抑制劑的治療組合及其用途 | |
| IL247713A0 (en) | Indazole 3-carboxyamides converted at the 5-position, their preparation and their use | |
| AU201710083S (en) | Bowl and Covered Bowl | |
| SG11201609645YA (en) | Device for connecting the structural elements of ribs and reticular structures | |
| ZA201702813B (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| HK1250710A1 (zh) | 用於製備雄激素受體拮抗劑及其中間體的方法 | |
| AU357565S (en) | Mixing bowls | |
| SG11201608217PA (en) | Fatty acid composition and use thereof | |
| IL249203A0 (en) | Androgen receptor modulators and methods of using them | |
| GB2530559B (en) | Mixing bowl | |
| IL265560A (en) | Preparations containing a mineralocorticoid receptor antagonist and their uses | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| IL247828A0 (en) | Progesterone compounds | |
| PL3347376T3 (pl) | Nowy receptor IGFR-podobny i jego zastosowania | |
| IL246944A0 (en) | A process for the preparation of abiraterone acetate and its intermediates | |
| GB201612052D0 (en) | Animal claw shearing apparatuses and methods of using the same | |
| GB201810451D0 (en) | Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof | |
| GB2544560B (en) | Mixing bowl | |
| GB201411741D0 (en) | Mixing bowl stand | |
| GB201402210D0 (en) | Mixing bowl | |
| GB201419977D0 (en) | Dynamic mixer and mixing | |
| GB201402629D0 (en) | Improved mixer and associated methods |